Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype

American Journal of Pathology

Volumn 159, Issue 2, 2001, Pages 651-659

  Soker, Shay ^a   Kaefer, Martin ^a   Johnson, Michelle ^a   Klagsbrun, Michael ^b   Atala, Anthony ^a   Freeman, Michael R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CONTROLLED STUDY; GROWTH STIMULATION; HISTOPATHOLOGY; LUNG; MALE; MALIGNANT TRANSFORMATION; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

EID: 0034891532     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)61736-1     Document Type: Article

References (61)

1. Molecular angiogenesis
2. Angiogenesis and inflammation
3. Mechanisms of angiogenesis
4. Vasculogenesis
5. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
6. Angiogenesis and vasculogenesis in treatment of cardiovascular disease
7. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis
8. Regulation of vascular endothelial growth factor expression in cultured keratinocytes: Implications for normal and impaired wound healing
9. Angiogenesis: Mechanistic insights, neovascular diseases, and therapeutic prospects
10. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
11. Vascular permeability factor, an endothelial cell mitogen related to PDGF
12. The biology of vascular endothelial growth factor
13. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
14. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels
15. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis
16. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
17. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
18. Suppression of retinal neovasculanzation in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
19. Flk-1 as a target for tumor growth inhibition
20. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
21. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
22. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family
23. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
24. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
25. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor
26. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF
27. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice Development
28. Vascular endothelial growth factor induces the disorganization of actin stress fibers accompanied by protein tyrosine phosphorylation and morphological change in Balb/C3T3 cells
29. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis
30. VEGF receptor subtypes KDR and FLT1 show different sensitivities to heparin and placenta growth factor
31. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain
32. Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors
33. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform specific receptor for vascular endothelial growth factor
34. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
35. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy
36. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting
37. An analysis of microvessel density, androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate cancer. Preliminary results and therapeutic implications
38. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor
39. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer
40. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues
41. Expression of vascular endothelial growth factor receptors in human prostate cancer
42. Culture of a prostatic cell line in basement membrane gels results in an enhancement of malignant properties and constitutive alterations in gene expression
43. 165
44. Co-inoculation of tumorigenic rat prostate mesenchymal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals
45. Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: Implication as a tumor suppressor
46. Angiogenesis and angiogenesis inhibition: An overview
47. Angiogenesis and tumor metastasis
48. Advances in angiogenesis research: Relevance to urological oncology
49. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity
50. Vascular endothelial growth factor content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma
51. Neutralizing antivascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model
52. Vascular endothelial growth factor (VEGF) and its receptors
53. Signaling via vascular endothelial growth factor receptors
54. VEGFs, receptors and angiogenesis
55. Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms
56. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
57. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms
58. Neuropilin-1 is a placenta growth factor-2 receptor
59. Vascular endothelial growth factor increases the mitogenic response to fibroblast growth factor-2 in vascular smooth muscle cells in vivo via expression of fms-like tyrosine kinase-1
60. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor
61. Smooth muscle-epithelial interactions in normal and neoplastic prostatic development